The FDA declines to approve an opioid and a treatment for rheumatoid arthritis; KKR closes WebMD buyout; 60% of teens have received the HPV vaccine
Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts
The OPDP has only issued two letters in 2017, compared to 11 last year.
Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info
The lobbying group said it's unclear what the agency's goal is with this research and how it promotes public health.
Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer
That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.
The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.
The FDA on pace for record generic drug approvals; CVS Health CEO doubts Amazon's entrance to pharmacy market; Sanofi to develop cancer immunotherapy
A shorter list of risks in TV ads helps consumer comprehension; medical-school choice affects prescribing patterns; reps often show docs the same info
AbbVie's new HCV drug is cheaper than Gilead's Harvoni; Lilly's experimental migraine drugs beats placebo; Fitbit to launch smartwatch
FDA committee votes against J&J arthritis drug; scientists successfully edit genes; Shire mulls ADHD spin off
If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.
Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement
Express Scripts removes 64 branded drugs from 2018 formulary; wearable market can regain momentum, analysts say; FDA accepts Herceptin biosimilars for review
FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review
The FDA to study whether linking to risk information affects patient recall; patients view docs who take industry payments as less honest; Mallinckrodt ups political donations
Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy
AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge
The drugmaker is one step closer to a potential approval of its experimental cancer treatment.
Gottlieb calls for new opioid training for docs; FDA committee to examine Novartis' CAR-T therapy; no Viagra ads expected during NFL season
Drug ads on mobile are not providing enough risk info; rare-disease drugmakers are concerned about healthcare bill; volume of opioid prescriptions drops
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
The FDA plans to review orphan drug backlog; drugmaker supported charity helped patients pay for donor's drugs; low dose Xarelto gets Priority Review
Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate
The performance of generic drugs is not always guaranteed; the FDA approves a new blood thinner; Gottlieb wants rejection letters public
The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement
The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.